News Formal

US plans shift of Merck COVID treatment to commercial market By Reuters

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 53%

United States News News

United States United States Latest News,United States United States Headlines

US plans shift of Merck COVID treatment to commercial market

© Reuters. FILE PHOTO: A COVID-19 treatment pill, called molnupiravir developed by Merck & Co and Ridgeback Biotherapeutics LP is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS/

Merck, which developed the drug with Ridgeback Biotherapeutics, said in an emailed statement on Wednesday that it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially. It has also been linked to potentially transmissable mutations in the COVID-19 virus, according to a study published in the journal Nature last month. Merck said the study was limited and that it is confident in the clinical profile of the drug.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 450. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Digital World, Trump's media firm add new termination clause to merger deal By ReutersDigital World, Trump's media firm add new termination clause to merger deal
Source: Investingcom - 🏆 450. / 53 Read more »